Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05193968 · ClinicalTrials.gov registry record · NA
Hot Flashes and Neurovascular Function in Women
A NA study of Menopause and Hot Flashes, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05193968: Recruiting NA study of Menopause and Hot Flashes, sponsored by Mayo Clinic.
NCT05193968 is a NA study of Menopause and Hot Flashes that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05193968, a NA study of Menopause and Hot Flashes, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Women who experience hot flashes are at greater risk for hypertension and other cardiovascular disease. Neurovascular control mechanisms are likely to play an important role in this relationship. As such, these studies are designed to provide a major step forward in understanding the link between hot flashes and neurovascular dysfunction and, by extension, cardiovascular disease in women.
Primary Outcome
Change in forearm vascular conductance with intra-arterial drug infusions. Vascular conductance is an index of vascular tone and is assessed using a technique called venous occlusion plethysmography
Conditions Studied
Interventions
- DRUG Norepinephrine
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- OTHER Sympathoexcitatory stressors
- DRUG Terbutaline
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05193968 shows while recruiting
NCT05193968 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 5 interventions - of which Norepinephrine is the first listed.
NCT05193968 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05193968 about?
NCT05193968 is a clinical study titled "Hot Flashes and Neurovascular Function in Women". Women who experience hot flashes are at greater risk for hypertension and other cardiovascular disease. Neurovascular control mechanisms are likely to play an important role in this relationship. As such, these studies are designed to provide a major step forward in understanding the link between ho...
What is the current status of trial NCT05193968?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-02-24. Estimated completion is 2026-12.
What conditions does trial NCT05193968 study?
This clinical trial studies the following conditions: Menopause, Hot Flashes, Vasomotor System; Labile.
What interventions are being tested in trial NCT05193968?
The interventions under investigation include: Norepinephrine (DRUG), Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), Sympathoexcitatory stressors (OTHER), Terbutaline (DRUG).
Who is sponsoring clinical trial NCT05193968?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05193968 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05193968's enrollment target sits among peer trials
120 15th of 54 higher than 40 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
-
Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training
RECRUITING · NA
-
Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females
RECRUITING · NA
-
Depression, Aging, Stress and Heart Health Study
RECRUITING · NA
-
Choline Dose Ranging in Postmenopausal Women
RECRUITING · NA
-
Following Lipectomy to Understand Adipose Tissue Re-accumulation
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI